Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives

Journal of Molecular Modeling

Volumn 18, Issue 9, 2012, Pages 4159-4170

  Siwek, Agata ^a   Stefanska, Joanna ^b   Dzitko, Katarzyna ^c   Ruszczak, Artur ^c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

Antifungal activity; Cytotoxicity; Molecular docking; Structure activity relationship; Thiosemicarbazide derivative

Indexed keywords

4 ARYLTHIOSEMICARBAZIDE DERIVATIVE; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTAMINE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; ISOQUINOLINE DERIVATIVE; ISOQUINOLINE THIOSEMICARBAZIDE DERIVATIVE; N ACETYLMURAMOYLALANINE AMIDASE; PROTEIN N MYRISTOYLTRANSFERASE; STEROL 14ALPHA DEMETHYLASE; THIOSEMICARBAZIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL;

ACYLTRANSFERASES; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CATALYTIC DOMAIN; CELL DEATH; CELL LINE; LIGANDS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; SEMICARBAZIDES; SPECIES SPECIFICITY; STATIC ELECTRICITY; THERMODYNAMICS;

CANDIDA;

EID: 84867582851     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-012-1420-5     Document Type: Article

References (64)

1. Pfaller MA, Diekma DJ (2007) Epidemiology of invasive candidiasis: Persistent public health problem. Clin Microbiol Rev 20:133-163
2. Negri M, Martins M, Henriques M, Svidzinski TI, Azeredo J, Oliveira R (2010) Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycopathologia 169:175-182
3. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U (2007) Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: Results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 60:424-428
4. Mercedes Panizo M, Reviakina V, Dolande M, Selgrad S (2008) Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 24:1-7
5. Richardson M, Lass-Flörl C (2008) Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 14:5-24
6. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535
7. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA (2001) International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39:3254-3259
8. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317
9. Méan M, Marchetti O, Calandra T (2008) Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12:204-212
10. Lass-Flörl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197-205
11. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298-1302
12. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA (1999) The epidemiology of candidemia in two United States cities: Results of a populationbased active surveillance. Clin Infect Dis 29:1164-1170
13. Tortorano AM, Kibbler C, Peman J, BernhardtH KL, Grillot R (2006) Candidaemia in Europe: Epidemiology and resistance. Int J Antimicrob Agents 27:359-366
14. Enoch DA, Ludlam HA, Brown NMJ (2006) Invasive fungal infections: A review of epidemiology and management options. J Med Microbiol 55:809-818
15. Blot S, Vandewoude K (2004) Management of invasive candidiasis in critically ill patients. Drugs 64:2159-2175
16. Hakki M, Staab JF, Marr KF (2006) Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Ch 50:2522-2524
17. Moudgal V, Little T, Boikov D, Vazquez JA (2005) Multiechinocandinand Multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767-769
18. Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B, Schonheyder HC, Tvede MJ (2005) Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43:4434-4340
19. Hobson RPJ (2003) The global epidemiology of invasive Candida infections-is the tide turning? J Hosp Infect 55:159-168
20. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers JGM (2009) Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect Dis 6:789-795
21. Groll AH, De Lucca AJ, Walsh TJ (1998) Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol 6:117-124
22. Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
23. Schiaffella F,Macchiarulo A,Milanese L, Vecchiarelli A, Costantino G, Pietrella D, Fringuelli R (2005) Design, synthesis, and microbiological evaluation of new Candida albicans CYP51 inhibitors. JMed Chem 48:7658-7666
24. Siwek A, Staczek P, Stefanska J (2011) Synthesis and structureactivity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides. Eur J Med Chem 46:5717-5726
25. Siwek A, Wujec M, Dobosz M, Wawrzycka-Gorczyca I (2010) Study of direction of cyclization of 1-azolil-4-aryl/alkyl-thiosemicarbazides. Heteroatom Chem 21:521-532
26. Siwek A, Wujec M, Stefanska J, Paneth P (2009) Antimicrobial properties of 4-aryl-(2-methyl-furan-3-yl)-?2-1H-1,2,4-triazolethiones. Phosphorus Sulfur 184:3149-3159
27. Wawrzycka I, Siwek A, Kosikowska U, Malm A (2011) Synthesis and crystal structure of N-butyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)-1,3,4-thiadiazol-2-amine and 5-isoquinolin-3-yl-N-(2-methylphenyl)-1,3,4-thiadiazol-2-amine. Z Kristallogr 226:297-302
28. Çapan G, Ulusoy N, Ergenç N, Kiraz M (1999) New 6-Phenylimidazo2,1-b]thiazole derivatives: Synthesis and antifungal activity. Monatsh Chem 130:1399-1407
29. Dogan HN, Rollas S, Erdeniz H (1998) Synthesis, structure elucidation and antimicrobial activity of some 3-hydroxy-2-naphthoic acid hydrazide derivatives. Farmaco 53:462-467
30. Farag AM, Mayhoub AS, Barakat SE, Bayomi AH (2008) Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial. Bioorg Med Chem 16:4569-4578
31. Siwek A, Stefanska J (2011) Antimicrobial activity and SAR study of some novel thiosemicarbazide derivatives bearing piperidine moiety. Med Chem 7:690-696
32. Salgin-Göksen U, Gökhan-Kelekçi N, Göktas Ö, Köysal Y, Kiliç E, Isik S, Aktay G, Özalp M (2007) 1-Acylthiosemicarbazides, 1,2,4-triazole-5(4H)-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: Synthesis, analgesicanti-inflammatory and antimicrobial activities. Bioorg Med Chem 15:5738-5751
33. Wujec M, Kosikowska U, Paneth P, Malm A (2007) Reaction of hydrazide of (tetrazol-5-yl)acetic acid with isothiocyanates and antimicrobial investigations of newly-obtained compouns. Heterocycles 71:2617-2626
34. Cunha S, Macedo FC Jr, Costa GAN, Rodrigues MT Jr, Verde RBV, de Souza Neta LC, Vencato I, Lariucci C, Sá FP (2007) Antimicrobial activity and structural study of disubstituted thiourea derivatives. Monatsh Chem 138:511-516
35. Kadi AA (2011) Synthesis and antimicrobial activity of some new quinazolin-4(3H)-one derivatives. J Saudi Chem Soc 15:95-100
36. Al-Saadi MS, Faidallah HM, Rostom SAF (2008) Synthesis and biological evaluation of some 2,4,5-trisubstituted thiazole derivatives as potential antimicrobial and anticancer agents. Arch Pharm 341:424-434
37. Jalilian AR, Sattari S, Bineshmarvasti M, Shafiee A, Daneshtalab M (2000) Synthesis and in vitro antifungal and cytotoxicity evaluation of thiazolo-4H-1,2,4-triazoles and 1,2,3-thiadiazolo-4H-1,2,4-triazoles. Arch Pharm 333:347-354
38. Ruge E, Korting HC, Borelli C (2005) Current state of threedimensional characterisation of antifungal targets and its use for molecular modelling in drug design. Int J Antimicrob Ag 26:427-441
39. ShengChXuH,WangW, CaoY,DongG,WangS,CheX, JiH,Miao Z, Yao J, ZhangW(2010) Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors. Eur J Med Chem 45:3531-3540
40. Balladka KS, Bettadapura GK, Chenna GD, Basavapattana RB, Hanumanthappa M (2010) Synthesis, characterization, in vitro and molecular docking studies of new 2,5-dichloro thienyl substituted thiazole derivatives for antimicrobial properties. Eur J Med Chem 45:3490-3496
41. Khan SI, Nimrod AC, Mehrpooya M, Nitiss L, Walker LA, Clark AM (2002) Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob Agents Ch 46:1785-1792
42. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial disc susceptibility tests; approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA
43. Clinical and Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA
44. HyperChem 8.0.3 (2007) HyperCube, Gainsville, FL
45. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236
46. Jorgensen WL, McDonald NA (1998) Development of an all-atom force field for heterocycles. Properties of liquid pyridine and diazenes. J Mol Struct (THEOCHEM) 424:145-155
47. Rocha GB, Freire RO, Simas AM, Stewart JJP (2006) Rm1: A reparameterization of AM1 for H, C, N, O, P, S, F, Cl, Br, and I. J Comput Chem 27:1101-1111
48. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA (2004) Gaussian03, Revision D.01. Gaussian, Wallingford, CT
49. Dennington II R, Keith T,Millam J, EppinnettK, Hovell WL,Gilliland R (2003) GaussView, Version 3.0. Semichem, Shawnee Mission, KS
50. Francl MM, Pietro WJ, Hehre WJ, Binkley JS, Gordon MS, Defrees DJ, Pople JA (1982) Self-consistent molecular orbital methods XXIII. A polarization-type basis set for second-row elements. J Chem Phys 77:3654-3665
51. Hariharan PC, Pople JA (1973) The influence of polarization functions on molecular orbital hydrogenation energies. Theor Chim Acta 28:213-222
52. Trott O, Olson AJ (2010) AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455-461
53. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235-242; http://www.pdb.org
54. Podust LM, von Kries JP, Nasser Eddine A, Kim Y, Yermalitskaya LV, Kuehne R, Ouellet H, Warrier T, Alteköster M, Lee J-S, Rademann J, Oschkinat H, Kaufmann SHE, Waterman MR (2007) Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother 51:3915-3923
55. Classen S, Olland S, Berger JM(2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 100:10629-10634
56. Isupov MN, Obmolova G, Butterworth S, Badet-Denisot MA, Badet B, Polikarpov I, Littlechild JA, Teplyakov A (1996) Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: Evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase. Structure 4:801-810
57. Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF (1995) The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure 3:1261-1271
58. Sogabe S, Masubuchi M, Sakata K, Fukami TA, Morikami K, Shiratori Y, Ebiike H, Kawasaki K, Aoki Y, Shimma N, D'Arcy A, Winkler FK, Banner DW, Ohtsuka T (2002) Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem Biol 9:1119-1128
59. Bertrand JA, Auger G, Fanchon E, Martin L, Blanot D, van Heijenoort J, Dideberg O (1997) Crystal structure of UDP-Nacetylmuramoyl-L-alanine:D-glutamate ligase from Escherichia coli. EMBO J 16:3416-3425
60. Ezabadi IR, Camoutsis C, Zoumpoulakis P, Geronikaki A, Sokovic M, Glamocilija J, Ciric A (2008) Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: Synthesis biological evaluation, lipophilicity, and conformational studies. Bioorg Med Chem 16:1150-1161
61. Kus C, Ayhan-Kilcigil G, Özbey S, Kaynak FB, Kaya M, Çoban T, Can-Eke B (2008) Synthesis and antioxidant properties of novel Nmethyl-1,3,4-thiadiazol-2-amine and 4-methyl-2H-1,2,4-triazole-3)-thione derivatives of benzimidazole class. Bioorg Med Chem 16:4294-4303
62. Önkol T, Dogruer DS, Uzun L, Adak S, Özkan S, Sahin MFJ (2008) Synthesis and antimicrobial activity of new 1,2,4-triazole and 1,3,4-thiadiazole derivatives. Enzyme Inhib Med Chem 23:277-284
63. Shams HZ, Mohareb RM, Helal MH, Mahmoud AE (2007) Synthesis, structure elucidation, and biological evaluation of some fused and/or pendant thiophene, pyrazole, imidazole, thiazole, triazole, triazine, and coumarin systems based on cyanoacetic 2-(benzoylamino) thioxomethyl. hydrazide. Phosphorus Sulfur 182:237-263
64. Babu KS, Li XC, Jacob MR, Zhang Q, Khan SI, Ferreira D, Clark AM (2006) Synthesis, antifungal activity, and structure-activity relationships of coruscanone A analogues. J Med Chem 49:7877-7886